TDAM USA’s Filana Therapeutics FLNA Stock Holding History

TDAM USA’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,370	Closed	-$21K	–	342
2017 Q1	$21K	Buy	+3,370	New	+$15.3K	﹤0.01%	346

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TDAM USA's FLNA Position: Q2 2017 in Review

TDAM USA sold out of Filana Therapeutics (FLNA) in Q2 2017, closing a stake of 3,370 shares — an estimated $21K sold.

TDAM USA first reported a position in FLNA in Q1 2017 and held it in 1 quarter. The position peaked at $21K in Q1 2017. 33 funds tracked by Wall St. Rank hold FLNA as of Q2 2017.

TDAM USA reported no remaining Filana Therapeutics position as of Q2 2017 after selling out during the quarter.
TDAM USA sold 3,370 Filana Therapeutics shares in Q2 2017, an estimated $21K.
TDAM USA first reported a position in Filana Therapeutics in Q1 2017 and held it in 1 quarter.
TDAM USA's Filana Therapeutics position peaked at $21K in Q1 2017.
33 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2017.

Based on TDAM USA's 13F filing for Q2 2017, filed 1 Aug 2017.